Followers | 2531 |
Posts | 69901 |
Boards Moderated | 0 |
Alias Born | 07/30/2012 |
Wednesday, May 31, 2017 10:23:23 PM
Recent Highlights:
Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe
Contract revenue for the three months ended March 31, 2017 was $0.3 million, compared with $0.1 million for the prior year period. The increase in contract revenue was due to the milestone revenue from ISU Abxis of $0.2 million.
Cash, cash equivalents and short-term investments as of March 31, 2017 were $14.5 million
The Company believes that its existing capital resources will be sufficient to meet its projected operating requirements for at least the next 12 months.
Raised $20.7 million through an underwritten public equity offering that included the full exercise of the underwriters’ over-allotment option to purchase additional shares and warrants on April 12, 2017
Achieved key milestones with CB 2679d/ISU304, the Company’s next-generation coagulation Factor IX, as follows:
Investigational New Drug (IND) application approved by the Korean Ministry of Food and Drug Safety (MFDS)
Completion of IND-enabling toxicology studies triggered a milestone payment from Catalyst’s collaboration partner, ISU Abxis
Advanced the development of marzeptacog alfa (activated), the Company’s next-generation Factor VIIa, including the following accomplishments:
Received notice from the European Patent Office that the opposition period, for a patent granted to Catalyst, has expired and no opposition has been filed
Selected a global contract research organization, INC Research, to conduct the Phase 2/3 efficacy clinical trial of marzeptacog alfa (activated) in individuals with hemophilia A or B with an inhibitor
Anticipated Milestones
CB 2679d/ISU304: Initiate a Phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B in the second quarter of 2017; the trial will be conducted by Catalyst’s collaborator, ISU Abxis (KOSDAQ: 086890) in South Korea
Marzeptacog alfa (activated): Initiate the Phase 2 part of a Phase 2/3 efficacy clinical trial in individuals with hemophilia A or B with an inhibitor in the fourth quarter of 2017
Recent CBIO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/02/2024 10:19:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2024 08:51:43 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/29/2024 12:49:16 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/29/2024 12:48:01 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2024 12:46:38 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/19/2024 08:06:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/09/2024 08:31:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/08/2024 10:03:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/05/2024 09:40:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/04/2024 09:27:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/03/2024 08:48:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2024 08:01:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/02/2024 09:35:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2024 10:42:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2024 09:03:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2024 01:55:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/22/2024 12:31:12 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/22/2024 12:27:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/21/2024 11:15:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2024 08:47:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/15/2024 09:29:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 10:16:03 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/24/2024 10:11:14 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/19/2024 09:05:30 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/12/2024 09:01:35 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM